Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Kelly M. Ramsbottom"'
Autor:
Matteo Costacurta, Edwin D. Hawkins, Ricky W. Johnstone, Grant A. McArthur, Jane Oliaro, Paul J Neeson, Paul A. Beavis, Stephin J. Vervoort, Joe Jiang Zhu, Deborah Meyran, Conor J. Kearney, Emily J. Lelliott, Ian A. Parish, Pilar M. Dominguez, Laura Kirby, Nicole M. Haynes, Lydia Lim, Luciano G. Martelotto, Kelly M Ramsbottom, Magnus Zethoven, Isabella Y. Kong, Karen E. Sheppard, Jarrod J. Sandow, Izabela Todorovski
Publikováno v:
Cancer Discovery. 11:2582-2601
Pharmacologic inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) are an approved treatment for hormone receptor–positive breast cancer and are currently under evaluation across hundreds of clinical trials for other cancer types. The clinical s
Autor:
Grant A. McArthur, Riyaben P. Patel, Carleen Cullinane, Claire Martin, Anthony T. Papenfuss, Amanda J Oliver, Kelly M Ramsbottom, Emily J. Lelliott, Nicole M. Haynes, Stefano Mangiola, Peter Lau, Lydia Lim, Jane Oliaro, Laura Kirby, Karen E. Sheppard, Magnus Zethoven, Luciano G. Martelotto, Alison Slater
Publikováno v:
Cancer immunology research. 9(2)
Combined inhibition of BRAF, MEK, and CDK4/6 is currently under evaluation in clinical trials for patients with melanoma harboring a BRAFV600 mutation. While this triple therapy has potent tumor-intrinsic effects, the impact of this combination on an
Autor:
Laura Kirby, Shatha AbuHammad, Richard J. Young, Peter Lau, Grant A. McArthur, Claire Martin, Katrina Meeth, Karen E. Sheppard, Jessica Michie, Kelly M Ramsbottom, Nicole M. Haynes, Rachael Walker, Fernando Souza-Fonseca-Guimaraes, Jane Oliaro, Emily J. Lelliott, Carleen Cullinane, Alison Slater
Publikováno v:
Scientific Reports
Scientific Reports, Vol 9, Iss 1, Pp 1-10 (2019)
Scientific Reports, Vol 9, Iss 1, Pp 1-10 (2019)
Both targeted therapy and immunotherapy have been used successfully to treat melanoma, but the development of resistance and poor response rates to the individual therapies has limited their success. Designing rational combinations of targeted therap
Autor:
Ben P. Martin, Susanne Heinzel, Michaela Waibel, Ricky W. Johnstone, Isabella Y. Kong, Edwin D. Hawkins, Stephin J. Vervoort, Kelly M Ramsbottom
Publikováno v:
Leukemia. 32(1)
Epigenetic targeting of Notch1-driven transcription using the HDACi panobinostat is a potential therapy against T-cell acute lymphoblastic leukemia
Autor:
Mikolaj Medon, Jason Li, Michael A. Henderson, Ricky W. Johnstone, Nicole M. Haynes, Phillip K. Darcy, Kelly M Ramsbottom, Stephin J. Vervoort, Mark J. Smyth, Misty R. Jenkins, Peter Atadja, Joseph A. Trapani, Eva Vidacs
Publikováno v:
Cancer research. 77(10)
Histone deacetylase inhibitors (HDACi) may engage host immunity as one basis for their antitumor effects. Herein, we demonstrate an application of this concept using the HDACi panobinostat to augment the antitumor efficacy of trastuzumab (anti-HER2)
Autor:
Sarah M. Russell, Andrea Newbold, Jane Oliaro, Ricky W. Johnstone, Kelly M Ramsbottom, Patrick O. Humbert, Edwin D. Hawkins
Publikováno v:
Oncogene. 35(9)
Scribble complex proteins maintain apicobasal polarity, regulate cell fate determination and function as tumour suppressors in epithelial tissue. Despite evidence that the function of Scribble is maintained in the lymphocyte lineage, we still underst
Autor:
Stephen B. Ting, Faruk Sacirbegovic, Ricky W. Johnstone, Jacques Ghysdael, Patrick O. Humbert, Kelly M Ramsbottom, Sarah M. Russell, Jane Oliaro, Michael Harvey, Edwin D. Hawkins, Tanja Kinwell
Publikováno v:
PLoS ONE, Vol 9, Iss 1, p e87376 (2014)
PLoS ONE
PLoS ONE
In epithelial and stem cells, lethal giant larvae (Lgl) is a potent tumour suppressor, a regulator of Notch signalling, and a mediator of cell fate via asymmetric cell division. Recent evidence suggests that the function of Lgl is conserved in mammal
Autor:
Kelly M Ramsbottom, Edwin D. Hawkins, Ricky W. Johnstone, Benjamin P. Martin, Michaela Waibel
Publikováno v:
Blood. 122:1435-1435
Introduction Although T cell acute lymphoblastic leukemia (T-ALL) is a genetically heterogeneous disease, mutations resulting in activation of the Notch-1 signalling pathway are present in over 50% of patients, thus defining Notch signaling as a cent